DE69837270T2 - Kerntransfer mit differenzierten fötalen und adulten spenderzellen - Google Patents
Kerntransfer mit differenzierten fötalen und adulten spenderzellen Download PDFInfo
- Publication number
- DE69837270T2 DE69837270T2 DE69837270T DE69837270T DE69837270T2 DE 69837270 T2 DE69837270 T2 DE 69837270T2 DE 69837270 T DE69837270 T DE 69837270T DE 69837270 T DE69837270 T DE 69837270T DE 69837270 T2 DE69837270 T2 DE 69837270T2
- Authority
- DE
- Germany
- Prior art keywords
- cells
- bovine
- cell
- unit
- nucleus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000012546 transfer Methods 0.000 title claims abstract description 56
- 239000007787 solid Substances 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 281
- 238000000034 method Methods 0.000 claims abstract description 112
- 210000000287 oocyte Anatomy 0.000 claims abstract description 73
- 210000003754 fetus Anatomy 0.000 claims abstract description 51
- 210000004940 nucleus Anatomy 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 21
- 210000003855 cell nucleus Anatomy 0.000 claims abstract description 18
- 241000283690 Bos taurus Species 0.000 claims description 116
- 210000002950 fibroblast Anatomy 0.000 claims description 60
- 210000002257 embryonic structure Anatomy 0.000 claims description 49
- 238000010367 cloning Methods 0.000 claims description 20
- 230000002062 proliferating effect Effects 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000007159 enucleation Effects 0.000 claims description 9
- 230000003213 activating effect Effects 0.000 claims description 8
- 238000004520 electroporation Methods 0.000 claims description 7
- 230000001605 fetal effect Effects 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 6
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 claims description 4
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 claims description 4
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 claims description 4
- 238000000520 microinjection Methods 0.000 claims description 3
- 210000003981 ectoderm Anatomy 0.000 claims description 2
- 210000001900 endoderm Anatomy 0.000 claims description 2
- 210000003716 mesoderm Anatomy 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 abstract description 62
- 238000002054 transplantation Methods 0.000 abstract description 20
- 241000894007 species Species 0.000 abstract description 16
- 210000002308 embryonic cell Anatomy 0.000 abstract description 14
- 210000000130 stem cell Anatomy 0.000 abstract description 6
- 230000000644 propagated effect Effects 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 description 31
- 210000001519 tissue Anatomy 0.000 description 27
- 239000002609 medium Substances 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 20
- 238000000338 in vitro Methods 0.000 description 20
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 19
- 239000012894 fetal calf serum Substances 0.000 description 18
- 239000001963 growth medium Substances 0.000 description 18
- 210000000056 organ Anatomy 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 210000002459 blastocyst Anatomy 0.000 description 14
- 230000004069 differentiation Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 108090000631 Trypsin Proteins 0.000 description 11
- 102000004142 Trypsin Human genes 0.000 description 11
- 230000035800 maturation Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 239000012588 trypsin Substances 0.000 description 11
- 230000004913 activation Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 239000007995 HEPES buffer Substances 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 210000001671 embryonic stem cell Anatomy 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 238000010449 nuclear transplantation Methods 0.000 description 7
- 241001494479 Pecora Species 0.000 description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 230000031864 metaphase Effects 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 208000018737 Parkinson disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000010363 gene targeting Methods 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 4
- 241001550206 Colla Species 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 108010059712 Pronase Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000012173 estrus Effects 0.000 description 4
- 230000004720 fertilization Effects 0.000 description 4
- 210000002503 granulosa cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 102100026189 Beta-galactosidase Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 210000004508 polar body Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- -1 Neurotophin-4/5 Proteins 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 241000283903 Ovis aries Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 208000012931 Urologic disease Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000003409 anti-rejection Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 210000001771 cumulus cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000002149 gonad Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
- VXUGVISSBXKUEL-UHFFFAOYSA-N 2-hydroxypropanoic acid;2-oxopropanoic acid Chemical compound CC(O)C(O)=O.CC(=O)C(O)=O VXUGVISSBXKUEL-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 101150035467 BDNF gene Proteins 0.000 description 1
- 101500028876 Bos taurus Neurotensin Proteins 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 101001002170 Homo sapiens Glutamine amidotransferase-like class 1 domain-containing protein 3, mitochondrial Proteins 0.000 description 1
- 101000572981 Homo sapiens POU domain, class 3, transcription factor 1 Proteins 0.000 description 1
- 101000843556 Homo sapiens Transcription factor HES-1 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical group C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 102000004230 Neurotrophin 3 Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100026458 POU domain, class 3, transcription factor 1 Human genes 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 102100020949 Putative glutamine amidotransferase-like class 1 domain-containing protein 3B, mitochondrial Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 108010046910 brain-derived growth factor Proteins 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 101150039352 can gene Proteins 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 210000002242 embryoid body Anatomy 0.000 description 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007908 penetration of oocytes Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8771—Bovine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8778—Swine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/101—Bovine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/106—Primate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/02—Cells from transgenic animals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/04—Cells produced using nuclear transfer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Neurosurgery (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/781,752 US5945577A (en) | 1997-01-10 | 1997-01-10 | Cloning using donor nuclei from proliferating somatic cells |
| US781752 | 1997-01-10 | ||
| PCT/US1998/000002 WO1998030683A2 (en) | 1997-01-10 | 1998-01-05 | Nuclear transfer with differentiated fetal and adult donor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69837270D1 DE69837270D1 (de) | 2007-04-19 |
| DE69837270T2 true DE69837270T2 (de) | 2008-01-24 |
Family
ID=25123802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69837270T Expired - Lifetime DE69837270T2 (de) | 1997-01-10 | 1998-01-05 | Kerntransfer mit differenzierten fötalen und adulten spenderzellen |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US5945577A (https=) |
| EP (2) | EP1015572B1 (https=) |
| JP (2) | JP2001512964A (https=) |
| CN (1) | CN1248288B (https=) |
| AT (1) | ATE356203T1 (https=) |
| AU (1) | AU742363C (https=) |
| BR (1) | BR9806872A (https=) |
| CA (1) | CA2277192C (https=) |
| DE (1) | DE69837270T2 (https=) |
| ES (1) | ES2284197T3 (https=) |
| IL (2) | IL130829A0 (https=) |
| NZ (1) | NZ336612A (https=) |
| WO (1) | WO1998030683A2 (https=) |
Families Citing this family (219)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9517779D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US20090092588A1 (en) * | 1997-01-10 | 2009-04-09 | University Of Massachusetts As Represented By Its Amherst Campus | Cloned ungulate embryos and animals, use of cells, tissues and organs thereof for transplantation therapies including parkinson's disease |
| US6235969B1 (en) | 1997-01-10 | 2001-05-22 | University Of Massachusetts | Cloning pigs using donor nuclei from non-quiescent differentiated cells |
| US6215041B1 (en) * | 1997-01-10 | 2001-04-10 | University Of Mmassachusetts | Cloning using donor nuclei from a non-quiesecent somatic cells |
| US5945577A (en) * | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| NZ337495A (en) * | 1997-03-06 | 2001-06-29 | Infigen Inc | Bovine primordial germ cells and their use in cloning |
| US6011197A (en) | 1997-03-06 | 2000-01-04 | Infigen, Inc. | Method of cloning bovines using reprogrammed non-embryonic bovine cells |
| IL133786A0 (en) | 1997-07-03 | 2001-04-30 | Univ Massachusetts | Cloning using donor nuclei from non-serum starved, differentiated cells |
| AU8587598A (en) * | 1997-07-26 | 1999-02-16 | Wisconsin Alumni Research Foundation | Trans-species nuclear transfer |
| RU2216592C2 (ru) * | 1998-01-16 | 2003-11-20 | Агробиоген Гмбх | Способ получения эмбрионов животных и способ выращивания животного из эмбрионов |
| US6331659B1 (en) * | 1998-01-21 | 2001-12-18 | University Of Hawaii | Cumulus cells as nuclear donors |
| CA2324009A1 (en) * | 1998-03-16 | 1999-09-23 | Relag Pty Ltd. | Porcine nuclear transfer |
| AUPP294898A0 (en) * | 1998-04-15 | 1998-05-07 | Monash University | Method of nuclear transfer |
| GB9808325D0 (en) * | 1998-04-20 | 1998-06-17 | Ltr Ciz Di Associazione Italia | Source of nuclei for nuclear transfer |
| GB9811859D0 (en) * | 1998-06-02 | 1998-07-29 | Biotech & Biolog Scien Res | Biological manipulation |
| CA2340242A1 (en) * | 1998-08-11 | 2000-02-24 | Teruhiko Wakayama | Method of performing transgenesis |
| AU3881499A (en) * | 1998-09-01 | 2000-03-21 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells with compatible histocompatibility genes |
| US6580017B1 (en) * | 1998-11-02 | 2003-06-17 | Genzyme Transgenics Corporation | Methods of reconstructed goat embryo transfer |
| US6781030B1 (en) | 1998-11-02 | 2004-08-24 | Trustee Of Tufts College, Ballou Hall | Methods for cloning mammals using telophase oocytes |
| US20030177513A1 (en) * | 1998-11-02 | 2003-09-18 | Yann Echelard | Transgenic and cloned mammals |
| EP1127112B1 (en) * | 1998-11-02 | 2007-03-21 | Trustees Of Tufts College | Methods for cloning animals |
| US6700037B2 (en) | 1998-11-24 | 2004-03-02 | Infigen, Inc. | Method of cloning porcine animals |
| US7531715B1 (en) | 1999-01-13 | 2009-05-12 | Ppl Therapeutics (Scotland) | Double nuclear transfer method and results thereof |
| US20020012660A1 (en) * | 1999-03-04 | 2002-01-31 | Alan Colman | Method of preparing a somatic cells for nuclear transfer |
| DK1159415T3 (da) * | 1999-03-04 | 2010-05-03 | Revivicor Inc | Genetisk modifikation af somatiske celler og anvendelse deraf |
| EP1198169B1 (en) * | 1999-05-06 | 2008-05-07 | Stem Cell Sciences (Australia) Pty Ltd | A process of cell reprogramming through production of a heterokaryon |
| WO2001000795A1 (en) * | 1999-06-30 | 2001-01-04 | Hwang, Woo-Suk | A method for producing cloned cows |
| AU753209B2 (en) * | 1999-06-30 | 2002-10-10 | Seoul National University Industry Foundation | Method for producing cloned tigers by employing inter-species nuclear transplantation technique |
| AU5577600A (en) * | 1999-06-30 | 2001-01-31 | Woo-Suk Hwang | A method for producing human embryonic skin cells by employing an inter-species nuclear transplantation technique |
| US20050255596A1 (en) * | 1999-09-07 | 2005-11-17 | West Michael D | Methods of repairing tandemly repeated DNA sequences and extending cell life-span nuclear transfer |
| NZ531844A (en) * | 1999-09-07 | 2005-08-26 | Advanced Cell Tech Inc | Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| US20040180430A1 (en) * | 1999-09-07 | 2004-09-16 | West Michael D. | Methods of restoring telomere length and extending cell lifespan using nuclear transfer |
| AU7372500A (en) * | 1999-09-13 | 2001-04-17 | University Of Massachusetts | Cloning pigs using donor cells or nuclei from differentiated cells and production of pluripotent porcine. |
| WO2002064799A2 (en) | 1999-09-28 | 2002-08-22 | Transkaryotic Therapies, Inc. | Optimized messenger rna |
| EP2275559A3 (en) | 1999-09-28 | 2011-03-23 | Shire Human Genetic Therapies, Inc. | Optimized messenger RNA |
| WO2001029206A1 (en) * | 1999-10-15 | 2001-04-26 | Advanced Cell Technology, Inc. | Methods of producing differentiated progenitor cells and lineage-defective embryonic stem cells |
| JP2003514516A (ja) | 1999-10-28 | 2003-04-22 | ユニバーシティ オブ マサチューセッツ | 多能性細胞と細胞株の雌性発生的または雄性発生的産生および分化した細胞と組織を産生するためのその使用 |
| EP1242591A1 (en) * | 1999-10-29 | 2002-09-25 | Nexia Biotechnologies, Inc. | Production of transgenic animals using nuclear transfer and oocytes recovered by lopu |
| CA2388510A1 (en) * | 1999-11-02 | 2001-05-10 | James M. Robl | Use of haploid genomes for genetic diagnosis, modification and multiplication |
| US7414170B2 (en) * | 1999-11-19 | 2008-08-19 | Kirin Beer Kabushiki Kaisha | Transgenic bovines capable of human antibody production |
| US7074983B2 (en) | 1999-11-19 | 2006-07-11 | Kirin Beer Kabushiki Kaisha | Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin |
| WO2001035735A1 (en) * | 1999-11-19 | 2001-05-25 | Hematech, Llc | Production of ungulates, preferably bovines that produce human immunoglobulins |
| US7820878B2 (en) * | 1999-11-19 | 2010-10-26 | Kyowa Hakko Kirin Co., Ltd. | Production of ungulates, preferably bovines that produce human immunoglobulins |
| KR100417566B1 (ko) * | 1999-11-19 | 2004-02-05 | 한국생명공학연구원 | 체세포 핵치환 복제수정란의 대량생산방법 |
| AU2766401A (en) * | 2000-01-04 | 2001-07-16 | University Of Connecticut, The | Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells |
| CA2396219A1 (en) | 2000-01-04 | 2001-07-12 | Xiangzhong Yang | Oocyte vitrification technique |
| US20060174358A1 (en) * | 2001-01-04 | 2006-08-03 | Xiangzhong Yang | Method for cloning animals with targetted genetic alterations by transfer of long-term cultured male or female somatic cell nuclei, comprising artificially-induced genetic alterations, to enucleated recipient cells |
| US6635802B1 (en) * | 2000-01-10 | 2003-10-21 | The Texas A&M University System | Nuclear transfer using cells cultured in serum starvation media containing apoptosis inhibitors |
| GB0001401D0 (en) * | 2000-01-22 | 2000-03-08 | Univ Edinburgh | Methods for amplifying genetic material and use thereof |
| ATE517990T1 (de) * | 2000-03-15 | 2011-08-15 | Univ Georgia | Effektive kernumprogrammierung in säugetieren |
| AU2001295194A1 (en) * | 2000-05-04 | 2001-11-12 | Biotime, Inc. | Methods and compositions for producing donor cells |
| EP1287033A2 (en) * | 2000-05-25 | 2003-03-05 | Queen's University At Kingston | Pt32 sperm protein, sperm c-yes, oocyte cytoplasmic c-yes, and uses thereof |
| US8030537B1 (en) | 2000-07-27 | 2011-10-04 | Apogene Gmbh & Co. Kg | Somatic cloning gene transfer for the production of recombinant proteins, cells and organs |
| US20030032180A1 (en) * | 2000-07-29 | 2003-02-13 | Strelchenko Larissa V. | Reconstituted cell lines prepared by nuclear transfer between differentiated cells |
| US20030172394A1 (en) * | 2001-08-01 | 2003-09-11 | Holzer George L | Selection and cloning methods |
| EA013564B1 (ru) | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
| US20040029825A1 (en) * | 2001-10-03 | 2004-02-12 | Davies Christopher J | Methods of minimizing immunological rejection of a nuclear transfer fetus |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| AU2001297880B2 (en) * | 2000-11-30 | 2007-05-31 | Stemron Inc. | Isolated homozygous stem cells differentiated cells derived therefrom and materials and methods for making and using same |
| US20030027331A1 (en) * | 2000-11-30 | 2003-02-06 | Yan Wen Liang | Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same |
| ATE466089T1 (de) | 2000-12-22 | 2010-05-15 | Agronomique Inst Nat Rech | Positionsunabhängige und gewebespezifische expression eines transgens in der milch eines transgen-tieres |
| US20020142397A1 (en) * | 2000-12-22 | 2002-10-03 | Philippe Collas | Methods for altering cell fate |
| US7491534B2 (en) * | 2000-12-22 | 2009-02-17 | Kirin Holdings Kabushiki Kaisha | Methods for altering cell fate to generate T-cells specific for an antigen of interest |
| DE60144248D1 (de) * | 2000-12-22 | 2011-04-28 | Kyowa Hakko Kirin Co Ltd | Verfahren zur klonierung von nichtmenschliche säugern unter verwendung von reprogrammiertem donorchromatin oder donorzellen |
| KR20030088023A (ko) | 2001-01-02 | 2003-11-15 | 스템론 인크. | 미리 선별된 면역형 및(또는) 유전자형을 갖는 동형접합성간세포 군집의 제조 방법, 그로부터 유래된 이식에 적합한세포, 및 이들을 사용하는 재료 및 방법 |
| AUPR247901A0 (en) * | 2001-01-10 | 2001-02-01 | Garelag Pty Ltd | Activation of nuclear transfer embryos |
| MXPA03006751A (es) | 2001-01-30 | 2005-04-08 | Amy K Rebholtz | Metodos para el manejo de recipientes para embriones. |
| AU2002250020A1 (en) * | 2001-02-02 | 2002-08-19 | Erik Forsberg | Method of cloning transgenic mammalian animals using pseudonuclei |
| CA2438832A1 (en) | 2001-02-23 | 2002-09-06 | Elan Pharmaceuticals, Inc. | Transgenic knockouts of bace-1 |
| JP2002262716A (ja) * | 2001-03-07 | 2002-09-17 | National Agricultural Research Organization | 株化細胞を用いて家畜個体を作出する方法 |
| WO2002073187A1 (en) * | 2001-03-09 | 2002-09-19 | Advanced Cell Technology, Inc. | Method for generating replacement cells and/or tissues |
| WO2002073188A1 (en) * | 2001-03-13 | 2002-09-19 | Advanced Cell Technology, Inc. | Method for generating replacement cells and/or tissues |
| WO2002078449A2 (en) * | 2001-04-02 | 2002-10-10 | Advanced Cell Technology, Inc. | Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells |
| AUPR446701A0 (en) | 2001-04-18 | 2001-05-17 | Gene Stream Pty Ltd | Transgenic mammals for pharmacological and toxicological studies |
| US20030092174A1 (en) * | 2001-05-14 | 2003-05-15 | Monika Liljedahl | Tissues or organs for use in xenotransplantation |
| US20030153044A1 (en) * | 2001-05-14 | 2003-08-14 | Monika Liljedahl | Tissues or organs for use in xenotransplantation |
| WO2002103350A1 (en) * | 2001-06-14 | 2002-12-27 | Infigen, Inc. | Methods for cloning mammals using remodeling factors |
| AU2002326353A1 (en) * | 2001-07-09 | 2003-01-29 | Alexion Pharmaceuticals Inc. | Cloned non-human mammals from contact inhibited donor cells |
| US20030017587A1 (en) * | 2001-07-18 | 2003-01-23 | Rader William C. | Embryonic stem cells, clinical applications and methods for expanding in vitro |
| US20060083722A1 (en) * | 2001-07-18 | 2006-04-20 | Advanced Cell Technology, Inc | Methods and compositions for cell therapy |
| WO2003011016A2 (en) * | 2001-07-31 | 2003-02-13 | Stell | Genetically modified cows having reduced susceptibility to mad cow disease |
| BR0211895A (pt) * | 2001-08-13 | 2006-04-04 | Embrex Inc | métodos de injetar um ovo avìcola, injetar uma pluralidade de ovos avìculas, de produzir uma ave quimérica e uma ave transgênica |
| US20030211603A1 (en) * | 2001-08-14 | 2003-11-13 | Earp David J. | Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells |
| CA2458362A1 (en) * | 2001-08-23 | 2003-03-06 | Reliance Life Sciences Pvt., Ltd. | Isolation of inner cell mass for the establishment of human embryonic stem cell (hesc) lines |
| CA2458575C (en) * | 2001-08-24 | 2014-07-08 | Advanced Cell Technology, Inc. | Screening assays for identifying differentiation-inducing agents and production of differentiated cells for cell therapy |
| US20050260179A1 (en) * | 2001-11-06 | 2005-11-24 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Stem and progenitor cell capture for tissue regeneration |
| CA2466198A1 (en) * | 2001-11-06 | 2003-05-15 | Shanghai Second Medical University | Somatic cell derived embryonic stem cells and their differentiated progenies |
| US20030232430A1 (en) * | 2001-11-26 | 2003-12-18 | Advanced Cell Technology | Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| US7018819B2 (en) * | 2001-11-30 | 2006-03-28 | Cellectricon Ab | Method and apparatus for manipulation of cells and cell-like structures focused electric fields in microfludic systems and use thereof |
| US20030113910A1 (en) * | 2001-12-18 | 2003-06-19 | Mike Levanduski | Pluripotent stem cells derived without the use of embryos or fetal tissue |
| CA2470195A1 (en) * | 2002-01-11 | 2003-08-07 | Gtc Biotherapeutics, Inc. | Method and system for fusion and activation following nuclear transfer in reconstructed embryos |
| US20040133931A1 (en) * | 2003-01-08 | 2004-07-08 | Gavin William G. | Method and system for fusion and activation following nuclear transfer in reconstructed embryos |
| AU2003235652A1 (en) * | 2002-01-15 | 2003-07-30 | Advanced Cell Technology, Inc. | Cloning b and t lymphocytes |
| US20030134422A1 (en) * | 2002-01-16 | 2003-07-17 | Sayre Chauncey Bigelow | Stem cell maturation for all tissue lines |
| US20050090004A1 (en) * | 2003-01-16 | 2005-04-28 | Sayre Chauncey B. | Stem cell maturation for all tissue lines |
| US20050170506A1 (en) * | 2002-01-16 | 2005-08-04 | Primegen Biotech Llc | Therapeutic reprogramming, hybrid stem cells and maturation |
| EP1476547B1 (en) * | 2002-01-23 | 2006-12-06 | The University of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| US6991066B2 (en) * | 2002-02-01 | 2006-01-31 | International Business Machines Corporation | Customized self-checkout system |
| US20030180268A1 (en) * | 2002-02-05 | 2003-09-25 | Anthony Atala | Tissue engineered construct for supplementing or replacing a damaged organ |
| US20030229909A1 (en) * | 2002-02-13 | 2003-12-11 | The Texas A&M University System | Cloning cats by nuclear transplantation |
| WO2003072708A2 (en) * | 2002-02-21 | 2003-09-04 | Advanced Cell Technology, Inc. | Pluripotent cells comprising allogenic nucleus and mitochondria |
| US20030161818A1 (en) * | 2002-02-25 | 2003-08-28 | Kansas State University Research Foundation | Cultures, products and methods using stem cells |
| US7736892B2 (en) * | 2002-02-25 | 2010-06-15 | Kansas State University Research Foundation | Cultures, products and methods using umbilical cord matrix cells |
| US20030232410A1 (en) * | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US20030204860A1 (en) * | 2002-04-01 | 2003-10-30 | David Melican | Method for selecting cell lines to be used for nuclear transfer in mammalian species |
| US20030217378A1 (en) * | 2002-04-05 | 2003-11-20 | The University Of Georgia Research Foundation, Inc | Cloning using rapidly matured oocytes |
| WO2003089578A2 (en) * | 2002-04-18 | 2003-10-30 | Idaho Research Foundation | Activation of equine oocytes |
| NZ536303A (en) * | 2002-04-24 | 2008-04-30 | Univ Georgia Res Found | Production of cloned offspring from cooled carcasses |
| AU2003295309A1 (en) * | 2002-04-30 | 2004-04-19 | Nucleotech, Llc | Methods for altering cell fate to generate t-cells specific for an antigen of interest |
| US20040091936A1 (en) * | 2002-05-24 | 2004-05-13 | Michael West | Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
| EP1513928B1 (en) | 2002-05-24 | 2019-08-21 | Advanced Cell Technology, Inc. | A bank of stem cells for producing cells for transplantation having hla antigens matching those of transplant recipients, and methods for making and using such a stem cell bank |
| US7612250B2 (en) * | 2002-07-29 | 2009-11-03 | Trustees Of Tufts College | Nuclear transfer embryo formation method |
| AU2003257155A1 (en) * | 2002-08-02 | 2004-02-23 | The General Hospital Corporation | Methods for the production of cells and mammals with desired genetic modifications |
| EP2806025B1 (en) * | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
| US20050034175A1 (en) * | 2002-09-09 | 2005-02-10 | Latif Zuhair A. | Immune cloning and uses thereof |
| US20040219563A1 (en) * | 2002-10-16 | 2004-11-04 | Michael West | Method using gene trapped stem cells for making pathways of stem cell differentiation and making and isolating differentiated cells |
| US20040077077A1 (en) * | 2002-10-18 | 2004-04-22 | Xiangzhong Yang | Novel methods for the production of cloned mammals, mammals cloned according to the methods, and methods of use of same |
| KR100479638B1 (ko) * | 2002-10-21 | 2005-03-31 | 주식회사 마크로젠 | 전기자극 및 막항원 표시자를 이용한 핵이식용 공여체 준비방법 및 이를 이용한 복제동물의 생산방법 |
| WO2004044156A2 (en) * | 2002-11-08 | 2004-05-27 | Hematech, Llc | Transgenic ungulates having reduced prion protein activity and uses thereof |
| US7627373B2 (en) | 2002-11-30 | 2009-12-01 | Cardiac Pacemakers, Inc. | Method and apparatus for cell and electrical therapy of living tissue |
| CN1683524A (zh) * | 2003-04-08 | 2005-10-19 | 东南大学 | 用体细胞核移植技术制备移核胚胎干细胞的方法 |
| KR20060057528A (ko) * | 2003-04-09 | 2006-05-26 | 마제-위민스 헬스 코퍼레이션 | 동물에서 체세포 핵 전이와 연관된 유사분열 방추 결함을교정하는 방법 |
| US20060037086A1 (en) * | 2003-04-09 | 2006-02-16 | Schatten Gerald P | Methods for correcting mitotic spindle defects and optimizing preimplantation embryonic developmental rates associated with somatic cell nuclear transfer in animals |
| US20120196370A1 (en) | 2010-12-03 | 2012-08-02 | Fyodor Urnov | Methods and compositions for targeted genomic deletion |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US11311574B2 (en) | 2003-08-08 | 2022-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| CN1871252A (zh) * | 2003-09-05 | 2006-11-29 | Gtc生物治疗学公司 | 在转基因哺乳动物奶中生产融合蛋白的方法 |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US20050186608A1 (en) * | 2004-02-19 | 2005-08-25 | Olsen Byron V. | Method for the production of transgenic proteins useful in the treatment of obesity and diabetes |
| US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
| US20050197496A1 (en) * | 2004-03-04 | 2005-09-08 | Gtc Biotherapeutics, Inc. | Methods of protein fractionation using high performance tangential flow filtration |
| NZ550106A (en) * | 2004-04-22 | 2009-06-26 | Kyowa Hakko Kirin Co Ltd | Transgenic animals and uses thereof |
| US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
| US7828711B2 (en) * | 2004-08-16 | 2010-11-09 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular growth and regeneration using ventricular assist device |
| JP2006081542A (ja) * | 2004-08-18 | 2006-03-30 | Institute Of Physical & Chemical Research | クローン哺乳動物の作成方法 |
| EP1778835A1 (en) * | 2004-08-20 | 2007-05-02 | Ingenium Pharmaceuticals AG | Methods for the production of improved live stocks and disease models for therapeutic research |
| US20060121004A1 (en) * | 2004-12-07 | 2006-06-08 | Yann Echelard | Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin |
| US20060123500A1 (en) * | 2004-12-07 | 2006-06-08 | Gtc Biotherapeutics, Inc. | Methods of prescreening cells for nuclear transfer procedures |
| US20060130159A1 (en) * | 2004-12-09 | 2006-06-15 | Nick Masiello | Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum |
| US8060219B2 (en) | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
| US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
| KR100733012B1 (ko) | 2005-07-26 | 2007-06-28 | 재단법인서울대학교산학협력재단 | 복제된 개과 동물 및 이의 생산 방법 |
| EP2302034B1 (en) | 2005-08-03 | 2020-10-14 | Astellas Institute for Regenerative Medicine | Improved methods of reprogramming animal somatic cells |
| CA2909775A1 (en) | 2005-08-09 | 2007-03-29 | Revivicor, Inc. | Transgenic ungulates expressing ctla4-ig and uses thereof |
| US7732202B2 (en) | 2005-10-21 | 2010-06-08 | International Stem Cell Corporation | Oxygen tension for the parthenogenic activation of human oocytes for the production of human embryonic stem cells |
| KR20080068089A (ko) | 2005-10-21 | 2008-07-22 | 지티씨바이오쎄라퓨틱스,인크. | 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법 |
| US7531632B2 (en) * | 2006-02-16 | 2009-05-12 | Gtc Biotherapeutics, Inc. | Clarification of transgenic milk using depth filtration |
| US20080124276A1 (en) | 2006-07-24 | 2008-05-29 | Lifeline Cell Technology | Synthetic cornea from retinal stem cells |
| ATE536374T1 (de) | 2006-09-01 | 2011-12-15 | Therapeutic Human Polyclonals Inc | Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren |
| WO2008085891A1 (en) * | 2007-01-05 | 2008-07-17 | Worcester Polytechnic Institute | Oocyte spindle-associated factors improve somatic cell cloning |
| KR100829426B1 (ko) * | 2007-01-17 | 2008-05-15 | 재단법인서울대학교산학협력재단 | 복제개의 생산 방법 |
| JP2010518857A (ja) | 2007-02-23 | 2010-06-03 | アドバンスド セル テクノロジー， インコーポレイテッド | 分化した細胞の再プログラムおよび再プログラムされた細胞からの動物および胚幹細胞の生成のための高能率的な方法 |
| US20080222745A1 (en) * | 2007-03-07 | 2008-09-11 | Utah State University | Colcemid-Treatment of Oocytes to enhance Nuclear Transfer Cloning |
| CA2683060C (en) | 2007-04-06 | 2018-01-16 | International Stem Cell Corporation | Patient-specific stem cell lines derived from human parthenogenetic blastocysts |
| KR100868245B1 (ko) * | 2007-05-29 | 2008-11-11 | 강원대학교산학협력단 | 데메콜친 처리에 의한 효율적인 복제 동물의 생산방법 |
| CN101668847A (zh) * | 2007-11-19 | 2010-03-10 | 财团法人首尔大学校产学协力财团 | 用于体细胞核移植的犬科出生率的提高方法 |
| WO2009088189A2 (ko) | 2008-01-04 | 2009-07-16 | Seoul National University Industry Foundation | 형질전환된 복제개의 생산방법 |
| WO2009134130A2 (en) | 2008-05-02 | 2009-11-05 | Pharming Intellectual Property Bv | Treatment of bleeding with low half-life fibrinogen |
| EP2267153A1 (en) | 2009-05-26 | 2010-12-29 | Université Claude Bernard Lyon 1 | Identification of netrin-1 receptor unc5c gene mutation in solid cancers |
| DK2498796T3 (en) | 2009-11-09 | 2018-03-05 | Aal Scient Inc | HEART DISEASE TREATMENT |
| EP2603581B1 (en) | 2010-08-11 | 2019-07-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cocultures of cumulus cells and embryos during in vitro fertilization procedures |
| EP4066826B1 (en) | 2010-09-01 | 2024-03-06 | Thomas Jefferson University | Retinoic acid receptor gamma agonists for muscle repair and regeneration |
| US20130296183A1 (en) | 2010-09-17 | 2013-11-07 | President And Fellows Of Harvard College | Functional genomics assay for characterizing pluripotent stem cell utility and safety |
| CN103492576A (zh) | 2011-02-14 | 2014-01-01 | 雷维维科公司 | 用于血管化异种移植物及其衍生物的异种移植的遗传修饰的猪 |
| KR102807016B1 (ko) | 2011-05-16 | 2025-05-14 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | 돼지 생식기 호흡기 증후군 바이러스 내성 동물 |
| WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
| WO2013021279A2 (en) | 2011-08-10 | 2013-02-14 | Lfb Biotechnologies | Highly galactosylated antibodies |
| EP2599859A1 (en) | 2011-11-30 | 2013-06-05 | IMBA-Institut für Molekulare Biotechnologie GmbH | Haploid cells |
| WO2013082509A1 (en) | 2011-12-01 | 2013-06-06 | The New York Stem Cell Foundation | Automated system for producing induced pluripotent stem cells or differentiated cells |
| US9828583B2 (en) | 2012-01-13 | 2017-11-28 | The General Hospital Corporation | Isolated human lung progenitor cells and uses thereof |
| AU2013255031C1 (en) | 2012-04-30 | 2018-12-06 | University Health Network | Methods and compositions for generating pancreatic progenitors and functional beta cells from hPSCs |
| JP6444307B2 (ja) | 2012-09-25 | 2018-12-26 | イエール ユニバーシティ | 胚体内胚葉を介したヒト肺胞ｉｉ型へのヒトｉｐｓ細胞の分化 |
| TW201444871A (zh) | 2013-02-13 | 2014-12-01 | Lab Francais Du Fractionnement | 具有修飾的糖化作用之西妥昔單抗及其用途 |
| EP2956485A2 (en) | 2013-02-13 | 2015-12-23 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-her2 antibodies and uses thereof |
| EP3594231A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| EP3896153A1 (en) | 2013-04-05 | 2021-10-20 | University Health Network | Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue |
| EP3008229B1 (en) | 2013-06-10 | 2020-05-27 | President and Fellows of Harvard College | Early developmental genomic assay for characterizing pluripotent stem cell utility and safety |
| SG11201510177WA (en) | 2013-06-11 | 2016-01-28 | Harvard College | SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME |
| WO2014201254A1 (en) | 2013-06-12 | 2014-12-18 | University Of Washington Through Its Center For Commercialization | Methods for maturing cardiomyocytes and uses thereof |
| WO2015023720A1 (en) | 2013-08-16 | 2015-02-19 | Yale University | Epithelial cell differentiation of human mesenchymal stromal cells |
| NZ716860A (en) | 2013-09-13 | 2022-07-01 | Univ Health Network | Methods and compositions for generating epicardium cells |
| WO2015069736A1 (en) | 2013-11-08 | 2015-05-14 | The Mclean Hospital Corporation | METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS |
| EP3096713B1 (en) | 2014-01-23 | 2022-09-21 | President and Fellows of Harvard College | Engineered polymeric valves, tubular structures and sheets |
| AU2015270152A1 (en) | 2014-06-02 | 2016-12-08 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Production of Fc fragments |
| US10597637B2 (en) | 2014-08-22 | 2020-03-24 | Procella Therapeutics Ab | Use of jagged 1/frizzled 4 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
| US10596200B2 (en) | 2014-08-22 | 2020-03-24 | Procella Therapeutics Ab | Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells |
| WO2016044271A2 (en) | 2014-09-15 | 2016-03-24 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
| CN104488853B (zh) * | 2015-01-12 | 2016-08-24 | 中国农业大学 | 一种牛胚胎玻璃化冷冻甩管解冻和直接移植方法 |
| CA2976283C (en) | 2015-02-17 | 2022-04-26 | University Health Network | Methods for making and using sinoatrial node-like pacemaker cardiomyocytes and ventricular-like cardiomyocytes |
| JP6929527B2 (ja) * | 2015-03-04 | 2021-09-01 | 株式会社ポル・メド・テック | 安定した表現型を示す疾患モデルブタおよびその作製方法 |
| WO2016178087A1 (en) | 2015-05-04 | 2016-11-10 | Biosourcing Sa | Transgenic production of chorionic gonadotropin |
| JP2018515073A (ja) | 2015-05-04 | 2018-06-14 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ | Ｆｃ融合タンパク質のトランスジェニック産生 |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| FI3331355T3 (fi) | 2015-08-06 | 2024-06-17 | Univ Missouri | Sikojen lisääntymishäiriö- ja keuhkotulehdusoireyhtymävirukselle (PRRSV) resistentti sika ja soluja, joilla on muokattuja CD163-geenejä |
| PT3417073T (pt) | 2016-02-19 | 2023-10-26 | Procella Therapeutics Ab | Marcadores genéticos para enxerto de células progenitoras ventriculares cardíacas humanas |
| US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| WO2017202814A1 (en) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of neuropathological disorders characterized by a loss of cortical neurons |
| WO2018085516A2 (en) | 2016-11-02 | 2018-05-11 | Aal Scientifics, Inc. | Non-mesenchymal human lung stem cells and methods of their use for treating respiratory diseases |
| US10508263B2 (en) | 2016-11-29 | 2019-12-17 | Procella Therapeutics Ab | Methods for isolating human cardiac ventricular progenitor cells |
| WO2019038587A1 (en) | 2017-08-23 | 2019-02-28 | Procella Therapeutics Ab | USE OF NEUROPILIN-1 (NRP1) AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS |
| WO2019096787A1 (en) | 2017-11-14 | 2019-05-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Regulatory t cells genetically modified for the lymphotoxin alpha gene and uses thereof |
| WO2019116096A1 (en) | 2017-12-15 | 2019-06-20 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Production of fc fragments |
| US11160260B2 (en) | 2018-04-17 | 2021-11-02 | The Curators Of The University Of Missouri | Methods for protecting porcine fetuses from infection with porcine reproductive and respiratory syndrome virus (PRRSV) |
| JP2021525094A (ja) | 2018-05-31 | 2021-09-24 | ユニバーシティー ヘルス ネットワーク | インスリン産生細胞を生成する、タンキラーゼ阻害剤を含む方法及び組成物 |
| US20210315938A1 (en) | 2018-09-07 | 2021-10-14 | Hebecell Corporation | Methods and Compositions for Retinal Neuron Generation in Carrier-Free 3D Sphere Suspension Culture |
| WO2020053661A1 (en) | 2018-09-13 | 2020-03-19 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Methods of purifying antibodies from the milk of transgenic non-human mammals comprising the use of chitosan |
| US12146160B2 (en) | 2019-05-14 | 2024-11-19 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Regulatory T cells targeted by lymphotoxin alpha blocking agent and uses thereof |
| WO2021069593A1 (en) | 2019-10-09 | 2021-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | T cells modified to express mutated cxcr4 or partially deleted and uses thereof |
| JP2023551404A (ja) | 2020-11-20 | 2023-12-08 | レビビコア， インコーポレイテッド | 異種間移植のための成長ホルモン受容体ノックアウトを有する多重トランスジェニックブタ |
| KR20240099180A (ko) | 2021-09-20 | 2024-06-28 | 레비비코르 인코포레이션 | 이종이식을 위한 10개의 유전자 변형을 포함하는 다중전이유전자 돼지 |
| US20250064859A1 (en) | 2022-03-16 | 2025-02-27 | The Children's Medical Center Corporation | Hpsc-derived articular chondrocyte compositions, systems and methods of use thereof |
| US20230330264A1 (en) | 2022-04-15 | 2023-10-19 | Smartcella Solutions Ab | COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS |
| CN119522044A (zh) | 2022-05-26 | 2025-02-25 | 藤得食品股份有限公司 | 基于植物的肉丝制品及其生产方法 |
| JP2025531074A (ja) | 2022-09-16 | 2025-09-19 | テンダー フード，インコーポレイテッド | 植物及び動物細胞ブレンド肉製品及びその製造方法 |
| JP2026504725A (ja) | 2022-12-16 | 2026-02-09 | テンダー フード，インコーポレイテッド | 植物ベースの家禽製品及びその製造方法 |
| WO2025217332A1 (en) | 2024-04-10 | 2025-10-16 | Tender Food, Inc. | Apparatus for production of food-grade fibers and methods of operating the same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994384A (en) * | 1986-12-31 | 1991-02-19 | W. R. Grace & Co.-Conn. | Multiplying bovine embryos |
| US5057420A (en) * | 1987-06-05 | 1991-10-15 | Granada Biosciences, Inc. | Bovine nuclear transplantation |
| US5523226A (en) * | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| AU1439295A (en) * | 1993-12-17 | 1995-07-03 | Abs Global, Inc. | Ungulate preblastocyst derived embryonic stem cells and use thereof to produce cloned transgenic and chimeric ungulates |
| EP0739412B1 (en) * | 1993-12-23 | 2002-02-27 | Infigen, Inc. | ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS |
| AUPM621394A0 (en) * | 1994-06-10 | 1994-07-07 | Mitchell, John | Cathode connection for aluminium smelter pot |
| CA2192982A1 (en) * | 1994-06-15 | 1995-12-21 | Koichiro Hashimoto | Ungulate eg cell |
| GB9417831D0 (en) * | 1994-09-05 | 1994-10-26 | Biotech & Biolog Scien Res | Biological manipulation |
| DE19532098A1 (de) * | 1995-08-30 | 1997-03-06 | Stuemed Gmbh | Vorrichtung für endoskopische Operationen, insbesondere spreizbares Stütz-Epi-Hypopharyngo-Laryngoskop nach Feyh-Kastenbauer |
| GB9517780D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| GB9517779D0 (en) * | 1995-08-31 | 1995-11-01 | Roslin Inst Edinburgh | Biological manipulation |
| US5905042A (en) * | 1996-04-01 | 1999-05-18 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Cultured inner cell mass cell lines derived from bovine or porcine embryos |
| US5945577A (en) * | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
-
1997
- 1997-01-10 US US08/781,752 patent/US5945577A/en not_active Expired - Fee Related
- 1997-09-22 US US08/935,052 patent/US6235970B1/en not_active Expired - Fee Related
-
1998
- 1998-01-05 DE DE69837270T patent/DE69837270T2/de not_active Expired - Lifetime
- 1998-01-05 CN CN988027941A patent/CN1248288B/zh not_active Expired - Lifetime
- 1998-01-05 AT AT98903349T patent/ATE356203T1/de not_active IP Right Cessation
- 1998-01-05 BR BR9806872-5A patent/BR9806872A/pt not_active Application Discontinuation
- 1998-01-05 NZ NZ336612A patent/NZ336612A/xx unknown
- 1998-01-05 CA CA2277192A patent/CA2277192C/en not_active Expired - Lifetime
- 1998-01-05 JP JP53095898A patent/JP2001512964A/ja not_active Ceased
- 1998-01-05 EP EP98903349A patent/EP1015572B1/en not_active Expired - Lifetime
- 1998-01-05 ES ES98903349T patent/ES2284197T3/es not_active Expired - Lifetime
- 1998-01-05 IL IL13082998A patent/IL130829A0/xx active IP Right Grant
- 1998-01-05 EP EP07004337A patent/EP1808484A1/en not_active Withdrawn
- 1998-01-05 WO PCT/US1998/000002 patent/WO1998030683A2/en not_active Ceased
- 1998-01-05 AU AU60145/98A patent/AU742363C/en not_active Ceased
-
1999
- 1999-07-07 IL IL130829A patent/IL130829A/en not_active IP Right Cessation
-
2001
- 2001-04-10 US US09/828,876 patent/US20020010949A1/en not_active Abandoned
-
2004
- 2004-09-02 US US10/932,921 patent/US20050108785A1/en not_active Abandoned
-
2007
- 2007-03-28 JP JP2007084406A patent/JP2007167078A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2277192C (en) | 2011-03-15 |
| NZ336612A (en) | 2002-09-27 |
| EP1015572A2 (en) | 2000-07-05 |
| US20020010949A1 (en) | 2002-01-24 |
| US20050108785A1 (en) | 2005-05-19 |
| CA2277192A1 (en) | 1998-07-16 |
| AU742363B2 (en) | 2002-01-03 |
| IL130829A (en) | 2008-11-26 |
| EP1808484A1 (en) | 2007-07-18 |
| ES2284197T3 (es) | 2007-11-01 |
| WO1998030683A2 (en) | 1998-07-16 |
| ATE356203T1 (de) | 2007-03-15 |
| WO1998030683A3 (en) | 1998-09-17 |
| EP1015572B1 (en) | 2007-03-07 |
| AU742363C (en) | 2007-06-28 |
| IL130829A0 (en) | 2001-01-28 |
| BR9806872A (pt) | 2000-04-18 |
| US5945577A (en) | 1999-08-31 |
| JP2001512964A (ja) | 2001-08-28 |
| AU6014598A (en) | 1998-08-03 |
| CN1248288B (zh) | 2011-11-09 |
| CN1248288A (zh) | 2000-03-22 |
| US6235970B1 (en) | 2001-05-22 |
| DE69837270D1 (de) | 2007-04-19 |
| JP2007167078A (ja) | 2007-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69837270T2 (de) | Kerntransfer mit differenzierten fötalen und adulten spenderzellen | |
| AU740709B2 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplanta tion | |
| US6235969B1 (en) | Cloning pigs using donor nuclei from non-quiescent differentiated cells | |
| US20010012513A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation | |
| WO1999001163A1 (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
| AU2211499A (en) | Cloning using donor nuclei from differentiated fetal and adult cells | |
| EP1060243A1 (en) | Embryonic or stem-like cell lines produced by cross-species nuclear transplantation | |
| US20020194637A1 (en) | Embryonic or stem-like cell lines produced by cross species nuclear transplantation | |
| AU2011202964A1 (en) | Nuclear transfer with differentiated fetal and adult donor cells | |
| MXPA99006464A (en) | Nuclear transfer with differentiated fetal and adult donor cells | |
| AU2006236032A1 (en) | Nuclear transfer with differentiated fetal and adult donor cells | |
| AU2006202185A1 (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
| MXPA00000201A (en) | Cloning using donor nuclei from non-serum starved, differentiated cells | |
| MXPA99001706A (es) | Lineas celulares embrionicas o similares a las desoporte producidas por transplante nuclear de especies cruzadas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |